TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results

TuHURA Biosciences (NASDAQ:HURA) issued its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

TuHURA Biosciences Price Performance

Shares of NASDAQ:HURA traded up $0.17 during midday trading on Friday, reaching $2.47. The company’s stock had a trading volume of 317,089 shares, compared to its average volume of 235,478. The business’s fifty day simple moving average is $2.28 and its 200-day simple moving average is $2.00. TuHURA Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $3.43. The company has a market capitalization of $157.29 million, a P/E ratio of -4.05 and a beta of -0.01.

Institutional Investors Weigh In On TuHURA Biosciences

A number of hedge funds have recently added to or reduced their stakes in HURA. Bank of America Corp DE acquired a new stake in TuHURA Biosciences in the 4th quarter valued at about $59,000. Jane Street Group LLC acquired a new position in shares of TuHURA Biosciences during the first quarter worth approximately $69,000. Geode Capital Management LLC grew its stake in shares of TuHURA Biosciences by 111.4% during the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after purchasing an additional 307,260 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of TuHURA Biosciences during the second quarter valued at approximately $27,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of TuHURA Biosciences in the second quarter valued at approximately $97,000. Institutional investors own 0.62% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Citigroup initiated coverage on shares of TuHURA Biosciences in a report on Monday, April 27th. They set an “outperform” rating for the company. Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set a “market outperform” rating and a $9.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Finally, Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.